DAWN Fail-to-Deliver

Day One Biopharmaceuticals, Inc. (DAWN) operates in the Healthcare sector, specifically the Biotechnology industry, with a market capitalization near $2.22B, listed on NASDAQ, employing roughly 181 people, carrying a beta of -1.75 to the broader market. Day One Biopharmaceuticals, Inc. Led by Jeremy Bender, public since 2021-05-27.

Fail-to-deliver (FTD) data from the SEC tracks settlement failures where shares were not delivered within the standard settlement period. Persistent FTDs may indicate naked short selling or settlement issues and are monitored by regulators.

Latest Date

2026-04-28

Latest FTD Quantity

65

Latest Price

$21.53

30-Day Avg FTD

28.2K

30-Day Total FTD

846.0K

Showing 30 days of SEC fail-to-deliver data for Day One Biopharmaceuticals, Inc..

Learn how fails-to-deliver is reported and how to read the data →